GE Healthcare has announced the launch of two new tools for the cardiology market, coinciding with the European Society of Cardiology (ESC) congress (25–28 August, Amsterdam, The Netherlands).
The launches include Vscan Air SL, a dual-headed, handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care, as well as CardioVisio, a digital tool designed to assist clinicians in decision-making for the treatment of patients with atrial fibrillation (AF).
“Vscan Air SL enables clinicians to make quick cardiac assessments and adds to our broad portfolio of ultrasound technologies to help further inform clinical decision making at the point of care,” said Dietmar Seifriedsberger, GE Healthcare’s global general manager, Point of Care and Handheld Ultrasound of the launch of the new handheld ultrasound device, the latest in its Vscan portfolio of devices. “This newest innovation demonstrates our commitment to providing integrated solutions resulting in better standard of care delivery—and ultimately helping clinicians improve patient outcomes.”
The device is currently commercially available in select countries throughout Europe and Asia as well as Australia and New Zealand, while in the USA, Vscan Air SL is 510(k) cleared by the US Food and Drug Administration (FDA) and is expected to become commercially available this quarter.
Cardiovisio, meanwhile, is a portal designed to assist clinicians in visualising longitudinal data relevant for disease progression from multiple data sources, saving time and aiding clinical decision making by offering guideline-directed therapy recommendations.
“Existing diagnosis and treatment care models for AF have been shown to be complex, time consuming and disconnected with disparate guidelines and poor guideline adherence,” said Eigil Samset, general manager, Cardiology Solutions at GE HealthCare. “With CardioVisio for AF, we are providing cardiologists with a powerful tool to tell the story of the heart, including previous diagnoses, prescribed medications, interventions, and comorbidities.”
The platform is commercially available in the USA, and the company plans to expand availability in the coming months incorporating additional regional guidelines.
